- Home
- ANTA vs ANIK Comparison
ANTA vs ANIK Comparison
Compare ANTA & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | ANIK |
|---|---|---|
| Founded | 2022 | 1983 |
| Country | Singapore | United States |
| Employees | 113 | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.7M | 198.9M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ANTA | ANIK |
|---|---|---|
| Price | $8.02 | $14.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $16.17 | ★ $17.00 |
| AVG Volume (30 Days) | 1.7K | ★ 91.7K |
| Earning Date | 06-16-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | $21.95 | $5.98 |
| Revenue Next Year | $30.46 | $7.42 |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $7.90 |
| 52 Week High | $15.65 | $16.24 |
Technical Indicators
Market Signals| Indicator | ANTA | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 50.46 |
| Support Level | $6.53 | $13.95 |
| Resistance Level | $9.81 | $15.01 |
| Average True Range (ATR) | 0.52 | 0.54 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 11.28 | 42.76 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.